SCHEMBL7736643

SCHEMBL7736643

O=C1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.55
SLC6A4 P31645 5/20 0.55
SLC6A3 Q01959 5/20 0.55
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP3A4 P08684 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
NPC1 O15118 1/20 0.51
MLNR O43193 1/20 0.51
NR1I2 O75469 1/20 0.51
ABCB11 O95342 1/20 0.51
ESR1 P03372 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM4 P08173 1/20 0.51
ABCB1 P08183 1/20 0.51
ADRB1 P08588 1/20 0.51
HTR1A P08908 1/20 0.51
CHRM5 P08912 1/20 0.51
ADRA2A P08913 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29757859 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL29481032 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL260266 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL30489007 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL260267 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL6261864 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL30592537 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL260276 1.00 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL8277375 0.87 MEN1 (0.42) SLC6A2SLC6A4SLC6A3MEN1KMT2A
SCHEMBL10071834 0.87 MEN1 (0.42) SLC6A2SLC6A4SLC6A3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542961-B1 TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE FOR USE IN TREATMENT OF CNS DISORDERS SEPRACOR INC (US) 2013-09-11 EP claimed
JP-2686366-B2 1997-12-08 JP claimed
EP-0724552-A1 PROCESS FOR PREPARING A CHIRAL TETRALONE PFIZER (US) 1996-08-07 EP claimed
WO-1995015299-A1 PROCESS FOR PREPARING A CHIRAL TETRALONE PFIZER INC. (US) 1995-06-08 WO claimed
EP-0295050-B1 PROCESS FOR PREPARING A 4,4-DIPHENYLBUTANOIC ACID DERIVATIVE PFIZER INC. (US) 1991-04-17 EP claimed
EP-0341015-A2 Improved process for preparing a ketimine PFIZER INC. (US) 1989-11-08 EP claimed
EP-0295050-A1 Process for preparing a 4,4-diphenylbutanoic acid derivative PFIZER INC. (US) 1988-12-14 EP claimed
JP-7002718-A None JP disclosed
JP-7002718-A None JP disclosed
US-11802274-B2 Engineered imine reductases and methods for the reductive amination of ketone and amine compounds CODEXIS, INC. (US) 2023-10-31 US disclosed
US-11802274-B2 Engineered imine reductases and methods for the reductive amination of ketone and amine compounds CODEXIS, INC. (US) 2023-10-31 US disclosed
US-20230295673-A1 ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2023-09-21 US disclosed
US-20230295673-A1 ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2023-09-21 US disclosed
WO-1993015059-A1 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS PFIZER INC. (US) 1993-08-05 WO disclosed
WO-1993012062-A1 PROCESS FOR PREPARING KETONE ENANTIOMER PFIZER INC. (US) 1993-06-24 WO disclosed
US-5196607-A Process for preparing ketone enantiomer PFIZER INC. (US) 1993-03-23 US disclosed
EP-0346226-B1 PROCESS FOR THE PREPARATION OF 4-ARYL DISUBSTITUTED-1-TETRALONES SYNTHELABO (FR) 1993-02-17 EP disclosed
US-5019655-A Method of preparing 4-dichlorophenyl-1-tetralones DELALANDE S.A. (FR) 1991-05-28 US disclosed
EP-0341015-A2 Improved process for preparing a ketimine PFIZER INC. (US) 1989-11-08 EP disclosed
EP-0295050-A1 Process for preparing a 4,4-diphenylbutanoic acid derivative PFIZER INC. (US) 1988-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802274-B2 Engineered imine reductases and methods for the reductive amination of ketone and amine compounds AKR1C4, AKR7A2, AKR1C2 SLC6A2 3083/4885SLC6A4 3318/4885SLC6A3 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.